Former US product
Geref was approved in the United States and later discontinued. The FDA determination says the withdrawal was not for safety or effectiveness reasons. [1]
Compound evidence dossier · O-006
Sermorelin: former authorisation and current supply
A GHRH analogue with a former narrow US authorisation. Its commercial withdrawal and today’s compounded supply answer different questions.
What does the evidence say?
Sermorelin was once approved in the United States for a narrow diagnostic and paediatric use, then commercially discontinued; the FDA later determined that the product was not withdrawn for safety or effectiveness reasons. That decision prevents a false safety verdict about the withdrawal. It does not establish that current compounded, research-labelled or online products are approved, equivalent, effective or low risk.
Claim check
Which claims survive an evidence check?
Each row keeps the claim, its best supporting evidence and the limiting caveat together.
Sermorelin was banned because it was unsafeIncorrect
The FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness. The record describes commercial discontinuation, not a safety ban. [1]
Former approval validates current anti-ageing useUnsupported
The past indication was narrow and did not authorise anti-ageing, physique, recovery or general wellness use. Historical approval cannot be widened by seller language.
A compounded product is the old approved medicineNot established
Current products may differ in formulation, strength, excipients, manufacturing controls, stability, sterility assurance and oversight. A shared ingredient name does not prove equivalence.
Sermorelin has the same evidence as CJC-1295No
Both are linked to GHRH signalling, but they are different active substances with different regulatory histories and pharmacology. Evidence should stay attached to the tested compound.
Human evidence
What have studies in people shown?
Most confusion comes from treating regulatory history as a clinical outcome. The withdrawal record answers why the old product left the market, not whether a current product works for a new purpose.
Narrow former uses
Historical diagnostic and paediatric uses cannot support current anti-ageing or body-composition marketing without separate trials.
Supply is not authorisation
Compounded and research-labelled supply sits outside the old approved-product package. Product identity and quality require fresh evidence.
Critical distinction
What withdrawal does to legal status
A commercial withdrawal can end routine supply without turning the medicine into proof of harm. It also does not keep the old authorisation alive for unrelated current products.
- What the FDA found
- Geref was not withdrawn for safety or effectiveness reasons.
- What that does not mean
- The product was not declared effective for modern anti-ageing, recovery or physique claims.
- Current US supply
- Compounded availability is not the same as an FDA-approved, commercially marketed product.
- Current UK question
- A former US approval does not create a UK marketing authorisation or settle UK supply law.
Risk register
What could go wrong?
Published historical use gives more context than a purely preclinical compound, but it does not define the risks of modern unverified formulations and uses.
| Risk channel | Evidence-aware interpretation |
|---|---|
| Endocrine effects | Stimulation of the GH axis can affect glucose regulation and fluid balance. Risk depends on person, exposure and product. |
| Population mismatch | Evidence from diagnostic or selected paediatric use cannot set safety expectations for unsupervised adult wellness use. |
| Product quality | Current non-authorised products can introduce wrong identity, strength, impurities, non-sterility and stability failures. |
| Missing evidence | Long-term outcomes, interactions and risk in people with relevant health conditions are not established for promoted uses. |
Product evidence
What would evidence about a vial prove?
A compound-level literature verdict and a product-level finding answer different questions. Neither can substitute for the other.
Claimed compound
The literature applies only if the vial contains the same active substance and form that the source studied.
Label and release record
A batch-specific record should identify the material, method, result, specification and accountable laboratory.
Submitted sample
A defensible result concerns the sample tested. It does not certify every vial, future batch or storage condition.
Clinical meaning
Identity, purity and sterility evidence cannot establish a health outcome or fill a missing human safety dataset.
Status check
Is it authorised or prohibited?
Medicine authorisation, lawful supply and anti-doping status are separate checks. Each can change and should be verified at the point of decision.
| System | Finding checked 8 August 2026 |
|---|---|
| UK medicine status | No current sermorelin medicine with a UK marketing authorisation was identified in the MHRA public database check. |
| United States | The former Geref product was discontinued, and the FDA found that its withdrawal was not for safety or effectiveness reasons. Current compounded supply is not the old approved product. |
| Sport | Sermorelin is a growth-hormone-releasing factor prohibited at all times under the 2026 WADA list. |
Method note
How was this judgement made?
We used the Federal Register determination for the reason for withdrawal and kept that administrative finding separate from evidence of efficacy, present-day product equivalence and UK legal status.
Searches prioritised regulator documents, current medicine and anti-doping records, trial registrations and indexed primary studies. Seller pages were not used as evidence of efficacy or safety.
Read the full editorial method and inspect the evidence library.
Source ledger
Primary sources
- US FDA determination on withdrawal of Geref (sermorelin acetate)Official finding that withdrawal was not for safety or effectiveness reasons. Checked 8 August 2026.
- US FDA, Ipamorelin advisory briefing with sermorelin regulatory historyContext on the former approved Geref product and current secretagogue review. Checked 8 August 2026.
- MHRA ProductsPublic UK medicines database used for the marketing-authorisation check. Checked 8 August 2026.
- World Anti-Doping Agency, 2026 Prohibited ListCurrent list used for sport-status checks; effective 1 January 2026. Checked 8 August 2026.
Questions answered
Frequently asked questions
Short answers keep the decisive caveat beside the claim.
Was sermorelin withdrawn because it was unsafe?
No. The FDA determined that Geref was not withdrawn for reasons of safety or effectiveness. That official finding should replace speculation about why the commercial product left the market.
Does former approval prove anti-ageing benefits?
No. The former uses were narrow and do not establish anti-ageing, muscle, recovery or general wellness outcomes. Each broader claim needs suitable human trials.
Is sermorelin authorised in the UK?
No current UK-authorised sermorelin medicine was identified in the MHRA public database check. Historical US approval does not create UK authorisation.
Is compounded sermorelin the same as Geref?
A shared active-ingredient name is insufficient. Formulation, strength, excipients, manufacturing controls, sterility, stability and supply oversight may differ.
Is sermorelin prohibited in sport?
Yes. Sermorelin is included among growth-hormone-releasing factors prohibited at all times by WADA. Athletes should check current rules and therapeutic-use-exemption requirements.
What does the historical record establish?
It establishes that a defined sermorelin product had narrow authorised uses and was commercially withdrawn for reasons other than safety or effectiveness. It does not validate today’s products or promoted outcomes.
Editorial experience
From our work: how we checked this page
For topical-map item O-006, Sermorelin: former authorisation and current supply was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 9 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.